Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
NU

NYSE · NUVB

Nuvation Bio Inc.

Healthcare · Biotechnology

$4.51

Down-$0.06 (-1.31%)

Updated Oct 27, 2026, 8:16 AM

SID Score

4.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.83B
P/E ratio
-13.02
Dividend yield
0.00%
52-week range
$4.05 – $7.58
Volume
3.66M
Avg. volume
8.66M

Price performance · NUVB

NUVB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

NUVB closed at $4.51 after 21 trading sessions, down 19.46% for the selected period.

Last close
$4.51
Period change
-19.46%
Period low
$4.45
Period high
$5.62
Daily close
View OHLC price history
NUVB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$4.62$4.68$4.48$4.513.66M
Oct 23, 2026$4.62$4.66$4.44$4.573.19M
Oct 22, 2026$4.83$4.91$4.655$4.705.81M
Oct 21, 2026$4.77$4.96$4.72$4.854.5M
Oct 20, 2026$4.51$4.82$4.46$4.776.85M
Oct 19, 2026$4.48$4.60$4.345$4.484.22M
Oct 16, 2026$4.75$4.76$4.42$4.454.47M
Oct 15, 2026$4.74$4.855$4.67$4.754.82M
Oct 14, 2026$4.66$4.80$4.61$4.683.78M
Oct 13, 2026$4.86$4.92$4.71$4.727.62M
Oct 12, 2026$4.96$5.005$4.88$4.903.18M
Oct 9, 2026$4.95$5.06$4.87$5.002.96M
Oct 8, 2026$4.80$4.98$4.625$4.959.29M
Oct 7, 2026$4.81$4.95$4.79$4.865.45M
Oct 6, 2026$4.96$4.97$4.73$4.886.65M
Oct 5, 2026$5.12$5.16$4.85$4.959.97M
Oct 2, 2026$5.66$5.66$5.03$5.1414.83M
Oct 1, 2026$5.57$5.616$5.452$5.563.47M
Sep 30, 2026$5.81$5.825$5.59$5.605.55M
Sep 29, 2026$5.59$5.69$5.54$5.623.07M
Sep 28, 2026$5.68$5.68$5.48$5.604.59M

Latest NUVB news

The latest Smart Investors Daily articles mentioning NUVB.

Stock researchCompany · Overview

NUVB research

Overview

Company profile and research snapshot.

Company profile

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$13.00
Implied upside
—
Analysts
—
NUVB recent ratings
DateFirmRatingTarget
Sep 30, 2026CitigroupBuy—
Sep 16, 2026CitizensMarket Outperform—
Sep 16, 2026WedbushOutperform—
Aug 21, 2026Cantor FitzgeraldOverweight—
Aug 18, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Nuvation Bio And 2 More Penny Stocks To Watch

AI heavyweights are wrestling with questions about debt, demand and whether today’s big bets will pay off, while many smaller AI infrastructure players now face what some analysts call a potential tech death spiral. That kind of uncertainty can push investors to look for lower priced shares in financially solid smaller businesses. This article highlights three such under 5 stocks, each screened for stronger balance sheet health and cash discipline. The three stocks highlighted here offer a...

Yahoo · Oct 15, 2026

Nextdoor Stock And 2 Healthy Penny Stocks To Own

Higher interest rates are hitting big tech and highly priced growth stories hard, as recent AI related sell offs have shown. That pullback is pushing more investors to look at smaller, lower priced shares where balance sheets matter more than buzz. This is where financially healthier penny stocks come in. In this article, you will see three such stocks that combine low share prices with relatively robust finances. The three stocks highlighted here offer a compelling starting point if you want...

Yahoo · Oct 10, 2026

Ventia Services Group And 2 Top Penny Stocks

Rising Treasury yields and the prospect of higher US interest rates are making expensive growth stories harder to justify, which is pushing more investors toward smaller companies with stronger finances. That is where high quality penny stocks can become interesting. You get businesses that have kept debt in check, limited dilution and attracted committed insiders. This article walks through three standout ideas from that group. The three elite penny stocks covered next are just a small...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By